Oncotarget

Research Papers:

Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma

Maria Tsoli, Jie Liu, Laura Franshaw, Han Shen, Cecilia Cheng, MoonSun Jung, Swapna Joshi, Anahid Ehteda, Aaminah Khan, Angel Montero-Carcabosso, Pierre J. Dilda, Philip Hogg, David S. Ziegler _

PDF  |  HTML  |  Supplementary Files  |  Order a Reprint

Oncotarget. 2018; 9:7541-7556. https://doi.org/10.18632/oncotarget.24045

Metrics: PDF 347 views  |   HTML 1673 views  |   ?  


Abstract

Maria Tsoli1, Jie Liu1, Laura Franshaw1, Han Shen1, Cecilia Cheng1, MoonSun Jung2, Swapna Joshi1, Anahid Ehteda1, Aaminah Khan1, Angel Montero-Carcabosso3, Pierre J. Dilda4, Philip Hogg5 and David S. Ziegler1,6

1Targeted Therapies Research Program, Children’s Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, New South Wales, Australia

2Experimental Therapeutics Program, Children’s Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, New South Wales, Australia

3Preclinical Therapeutics and Drug Delivery Research Program, Department of Oncology, Hospital Sant Joan de Déu, Barcelona, Spain

4Biophytis, UPMC, BC94, Paris, France

5ACRF Centenary Cancer Research Program, Centenary Institute, University of Sydney, Camperdown, New South Wales, Australia

6Kids Cancer Centre, Sydney’s Children Hospital, Randwick, New South Wales, Australia

Correspondence to:

David S. Ziegler, email: d.ziegler@unsw.edu.au

Keywords: DIPG; paediatric brain tumour; mitochondria; mTOR; PDGFR

Received: August 08, 2017     Accepted: January 02, 2018     Published: January 08, 2018

ABSTRACT

Diffuse Intrinsic Pontine Gliomas (DIPG) are the most devastating of all pediatric brain tumors. They mostly affect young children and, as there are no effective treatments, almost all patients with DIPG will die of their tumor within 12 months of diagnosis. A key feature of this devastating tumor is its intrinsic resistance to all clinically available therapies. It has been shown that glioma development is associated with metabolic reprogramming, redox state disruption and resistance to apoptotic pathways. The mitochondrion is an attractive target as a key organelle that facilitates these critical processes. PENAO is a novel anti-cancer compound that targets mitochondrial function by inhibiting adenine nucleotide translocase (ANT). Here we found that DIPG neurosphere cultures express high levels of ANT2 protein and are sensitive to the mitochondrial inhibitor PENAO through oxidative stress, while its apoptotic effects were found to be further enhanced upon co-treatment with mTOR inhibitor temsirolimus. This combination therapy was found to act through inhibition of PI3K/AKT/mTOR pathway, HSP90 and activation of AMPK. In vivo experiments employing an orthotopic model of DIPG showed a marginal anti-tumour effect likely due to poor penetration of the inhibitors into the brain. Further testing of this anti-DIPG strategy with compounds that penetrate the BBB is warranted.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 24045